Home > Insider Trading > Filing (0000899243-22-027077)

Filing Details

Accession Number:: 0000899243-22-027077
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2022-07-29 16:06:01
Reporting Period:: 2022-07-28

Accepted Time:: 2022-07-29 16:06:01
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1745999	Beam Therapeutics Inc.	BEAM	Biological Products, (No Disgnostic Substances) (2836)	000000000

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1786304	M. John Evans	C/O Beam Therapeutics Inc., 238 Main Street Cambridge MA 02142	Ceo	Yes	Yes	No	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Disposition	2022-07-28	10,181	$64.87	1,108,339	No	4	S	Direct
Common Stock	Disposition	2022-07-28	15,236	$65.82	1,093,103	No	4	S	Direct
Common Stock	Disposition	2022-07-28	1,562	$66.74	1,091,541	No	4	S	Direct
Common Stock	Disposition	2022-07-28	2,848	$67.80	1,088,693	No	4	S	Direct
Common Stock	Disposition	2022-07-28	173	$68.49	1,088,520	No	4	S	Direct
Common Stock	Disposition	2022-07-28	6,953	$64.88	136,047	No	4	S	Indirect	By John M. Evans, III 2018 Irrevocable Trust
Common Stock	Disposition	2022-07-28	10,599	$65.92	125,448	No	4	S	Indirect	By John M. Evans, III 2018 Irrevocable Trust
Common Stock	Disposition	2022-07-28	201	$66.61	125,247	No	4	S	Indirect	By John M. Evans, III 2018 Irrevocable Trust
Common Stock	Disposition	2022-07-28	2,247	$67.82	123,000	No	4	S	Indirect	By John M. Evans, III 2018 Irrevocable Trust

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct
No	4	S	Indirect	By John M. Evans, III 2018 Irrevocable Trust
No	4	S	Indirect	By John M. Evans, III 2018 Irrevocable Trust
No	4	S	Indirect	By John M. Evans, III 2018 Irrevocable Trust
No	4	S	Indirect	By John M. Evans, III 2018 Irrevocable Trust

Footnotes

The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. The sale price reported is a weighted average price. The Reporting Person undertakes to provide to Beam Therapeutics Inc. ("BEAM"), any security holder of BEAM or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $64.43 to $65.42, inclusive.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $65.43 to $66.34, inclusive.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $66.44 to $67.37, inclusive.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $67.45 to $67.87, inclusive.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $64.43 to $65.38, inclusive.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $65.46 to $66.45, inclusive.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $66.50 to $66.61, inclusive.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $67.72 to $68.49, inclusive.